치료(Treatment)

영문

1 Patients with mild or moderate Graves' ophthalmopathy
- Patients diagnosed with mild or moderate Graves' ophthalmopathy by an ophthalmologist
- NO SPECS class 2a or 2b patients (conjunctival edema, eyelid edema)
- Patients with exophthalmos ≤ 22 mm
- Patients who did not have other treatment for Graves'
2 Graves disease patient with normal thyroid function test
- Patients with Graves' disease who are on antithyroid medication and whose thyroid function tests are normal for more than 2 months.
- Graves' disease was treated with radioactive isotope therapy for patients who had been treated with radioisotope for more than 6 months but whose thyroid function test was normal
- Patients with Graves' disease who developed hypothyroidism after treatment of antithyroid drugs, radioisotope therapy, and surgical treatment should be treated with thyroid hormone therapy for at least 6 months before the study,
- Patients diagnosed with Graves' ophthalmopathy by an ophthalmologist but who were still before thyrotoxicosis and thyroid receptor antibody positive
3 Those who voluntarily signed the agreement

영문

① Those who do not voluntarily agree to clinical trials
② Severe Graves ophthalmopathy
- Patients with NO SPECS class 2C (soft tissue involvement, orbital edema, etc.)
- Patients with exophthalmos> 22 mm
- Patients with ocular torticollis when there is diplopia or silence
- Patients with visual neuropathy
- A severe Graves eye disease when an ophthalmologist judges
③ Patients who have received steroid or selenium treatment within the last 3 months
④ Patients who fall under the contraindication of drug administration
I. Patients who are hypersensitive to the drug or its components
II. Selenium toxic patient
III. Hereditary fructose intolerance, glucose-galactose uptake disorder or white sugar-isomaltase deficiency
⑤ Others Patients with other serious diseases such as the following
I. Patients with heart and circulatory dysfunction - those diagnosed with heart failure, coronary artery disease, arrhythmia, and currently taking medication
II. Patients with renal impairment - GFR <60 ml / min
III. Patients with hypoproteinemia - Albumin <3.3 g / dL
IV. Pregnant or potentially pregnant women
V. Maternity
VI. Patient receiving medical treatment
VII. Patients with gastrointestinal diseases such as peptic ulcer, chronic ulcerative colitis, localized colitis
⑥ Other, if judged by the researcher to be inappropriate for participation in this clinical trial